Aptinyx Inc. (APTX): Price and Financial Metrics


Aptinyx Inc. (APTX)

Today's Latest Price: $3.66 USD

0.21 (-5.43%)

Updated Jan 27 4:00pm

Add APTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

APTX Stock Summary

  • APTX's went public 2.61 years ago, making it older than just 6.87% of listed US stocks we're tracking.
  • The ratio of debt to operating expenses for Aptinyx Inc is higher than it is for about merely 0.52% of US stocks.
  • With a price/sales ratio of 98.59, Aptinyx Inc has a higher such ratio than 96.22% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aptinyx Inc are CYCN, HRTX, BLUE, RESN, and BCDA.
  • APTX's SEC filings can be seen here. And to visit Aptinyx Inc's official web site, go to www.aptinyx.com.

APTX Stock Price Chart Interactive Chart >

Price chart for APTX

APTX Price/Volume Stats

Current price $3.66 52-week high $6.47
Prev. close $3.87 52-week low $1.60
Day low $3.58 Volume 841,613
Day high $3.84 Avg. volume 901,713
50-day MA $3.63 Dividend yield N/A
200-day MA $3.64 Market Cap 231.52M

Aptinyx Inc. (APTX) Company Bio


Aptinyx Inc. develops therapeutics for neurological disorders. The company is focused on the development of drugs that interact with the NMDA receptor, and the company says it will use the funds to advance drugs for chronic pain, post-traumatic stress disorder (PTSD) and cognitive impairment in Parkinson’s disease. The company was founded in 2015 and is based in Evantson, Illinois.


APTX Latest News Stream


Event/Time News Detail
Loading, please wait...

APTX Latest Social Stream


Loading social stream, please wait...

View Full APTX Social Stream

Latest APTX News From Around the Web

Below are the latest news stories about Aptinyx Inc that investors may wish to consider to help them evaluate APTX as an investment opportunity.

Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the publication of a recent review article in Medicine in Drug Discovery featuring data on its novel NMDA receptor modulator, NYX-2925. The data span across numerous preclinical models and highlight the potential therapeutic benefits of NYX-2925 in treating chronic, centralized pain c

Business Wire | January 19, 2021

Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, 2021. The fireside chat will be available on-demand through the H.C. Wainwright conference portal, beginning at 6:00 AM ET on Monday, January 11, 2021. A webc

Business Wire | January 5, 2021

Aptinyx recommences Phase 2 study of NYX-2925

Aptinyx (APTX) has recommenced patient recruitment and screening in a Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy.Enrollment in the study had been suspended due to the escalation of the COVID-19 pandemic in the U.S.“This study in painful DPN represents the second ongoing Phase 2 study...

Seeking Alpha | January 4, 2021

Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that in December it recommenced patient recruitment and screening in a Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN). Enrollment in the study had been suspended due to the escalation of the COVID-19 pandemic in the United States.

Yahoo | January 4, 2021

Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will present virtually at the 39th Annual J.P. Morgan Healthcare Conference. Norbert Riedel, Ph.D., chief executive officer, is scheduled to present on Thursday, January 14, 2021 at 9:10 a.m. Eastern Time.

Yahoo | December 21, 2020

Read More 'APTX' Stories Here

APTX Price Returns

1-mo -1.88%
3-mo 19.22%
6-mo -2.92%
1-year -13.88%
3-year N/A
5-year N/A
YTD 5.78%
2020 1.17%
2019 -79.32%
2018 N/A
2017 N/A
2016 N/A

Continue Researching APTX

Want to see what other sources are saying about Aptinyx Inc's financials and stock price? Try the links below:

Aptinyx Inc (APTX) Stock Price | Nasdaq
Aptinyx Inc (APTX) Stock Quote, History and News - Yahoo Finance
Aptinyx Inc (APTX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7616 seconds.